Visual compatibility of blinatumomab with selected drugs during simulated Y-site administration
| Autor: | Raphaelle Fanciullino, Petula Vigne, Bertrand Pourroy, Amaury Guedon, Pierre Bertault Peres, Laurence Gauthier-Villano, Théau Du Repaire |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Pharmacology
Caffeine chemistry Hydrocortisone business.industry Health Policy Antineoplastic Agents 030226 pharmacology & pharmacy Caffeine metabolism Drug Incompatibility 03 medical and health sciences 0302 clinical medicine Caffeine Antibodies Bispecific medicine Humans Blinatumomab 030212 general & internal medicine business Infusions Intravenous Vision Ocular medicine.drug |
| Zdroj: | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 74(16) |
| ISSN: | 1535-2900 |
| Popis: | Blinatumomab is a bispecific T-cell engager antibody construct that binds specifically to CD19 expressed on the surface of cells of B-lineage origin and CD3 expressed on the surface of T cells.[1][1] Blinatumomab was approved by the European Medicines Agency for the treatment of adults with |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|